Controlled Release of Proteins to Tissue Transplants for the Treatment of Neurodegenerative Disorders
- 1 December 1996
- journal article
- review article
- Published by American Geophysical Union (AGU) in Journal of Pharmaceutical Sciences
- Vol. 85 (12) , 1276-1281
- https://doi.org/10.1021/js9601602
Abstract
Alzheimer's disease involves substantial cholinergic cell deficits; other neurodegenerative diseases involve similar losses of certain cell populations. Optimal therapies may involve tissue replacement coupled with the controlled delivery of appropriate growth factors, such as nerve growth factor, to the graft site. In this review article we describe the kinetics of protein release from three modes of controlled protein delivery to transplants: delivery from a polymer matrix, delivery form polymeric microspheres, and delivery from genetically engineered cells. The efficacy and feasibility of each of these delivery strategies for potential treatment of patients diagnosed with neurodegenerative disorders is discussed.Keywords
This publication has 40 references indexed in Scilit:
- Bridging grafts and transient nerve growth factor infusions promote long-term central nervous system neuronal rescue and partial functional recovery.Proceedings of the National Academy of Sciences, 1995
- Neuropathological Evidence of Graft Survival and Striatal Reinnervation after the Transplantation of Fetal Mesencephalic Tissue in a Patient with Parkinson's DiseaseNew England Journal of Medicine, 1995
- Enhanced survival and neuronal differentiation of adrenal chromaffin cells cografted into the striatum with NGF-producing fibroblastsJournal of Neuroscience, 1995
- Role of growth factors in degeneration and regeneration in the central nervous system; clinical experiences with NGF in Parkinson's and Alzheimer's diseasesZeitschrift für Neurologie, 1994
- Bilateral Fetal Mesencephalic Grafting in Two Patients with Parkinsonism Induced by 1-Methyl-4-Phenyl-L,2,3,6-Tetrahydropyridine (MPTP)New England Journal of Medicine, 1992
- Survival of Implanted Fetal Dopamine Cells and Neurologic Improvement 12 to 46 Months after Transplantation for Parkinson's DiseaseNew England Journal of Medicine, 1992
- Unilateral Transplantation of Human Fetal Mesencephalic Tissue into the Caudate Nucleus of Patients with Parkinson's DiseaseNew England Journal of Medicine, 1992
- Human nerve growth factor prevents degeneration of basal forebrain cholinergic neurons in primatesAnnals of Neurology, 1991
- Recombinant human nerve growth factor prevents retrograde degeneration of axotomized basal forebrain cholinergic neurons in the ratExperimental Neurology, 1991
- Morphological response of axotomized septal neurons to nerve growth factorJournal of Comparative Neurology, 1988